| Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. | |
| | |
MedLine Citation:
|
PMID: 20587746 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Second-generation antipsychotics (SGAs) are thought to have a lower likelihood of inducing extrapyramidal symptoms (EPS) than are first-generation antipsychotics (FGAs). Clinical observations suggest that younger patients may be more sensitive to SGA-associated EPS than are adults and require therapy with anticholinergic agents. OBJECTIVE: To determine the proportion of patients 5-18 years of age who received anticholinergic therapy during the initial stages of antipsychotic treatment, as well as to compare anticholinergic utilization across patients receiving aripiprazole, risperidone, and quetiapine, SGAs previously identified as the most commonly prescribed at the academic institution studied. METHODS: Patients 5-18 years of age who were initiating a course of an antipsychotic between January 1, 2005, and September 1, 2008, were identified in a retrospective review of prescription and medical records. Data on demographic characteristics, antipsychotic and anticholinergic utilization, indications, diagnoses, and concomitant medications were collected from the medical record. Only the first therapeutic course of an antipsychotic identified was analyzed. Anticholinergic utilization at antipsychotic initiation and after 30 days was assessed. RESULTS: A total of 235 antipsychotic treatment courses were identified. Of these, 152 patients met our inclusion criteria. Anticholinergic utilization at any time during the first 30 days of treatment was identified in 32 patients (21%), while EPS was documented for 12 patients (8%). FGA or polypharmacy (simultaneous use of >or=2 scheduled antipsychotic) use versus SGA use (OR 18.98; 95% CI 4.74 to 75.95) was the primary characteristic significantly associated with anticholinergic utilization within 30 days after initiation. Of the most commonly used SGAs, risperidone was the drug with which anticholinergics were most frequently prescribed (p = 0.03). CONCLUSIONS: Anticholinergic prescribing exceeded the incidence of EPS, as documented in the medical record (21% vs 8%), and differed across individual medications and antipsychotic class. Utilization of FGAs or polypharmacy was a key predictor of anticholinergic use. |
| | |
Authors:
|
Irene Seunghyun Hong; Jeffrey R Bishop |
Related Documents
:
|
9551496 - Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia. 8791256 - Long-term antipsychotic medication of schizophrenics does not promote the development o... 14609246 - Trends in the rate and type of antipsychotic medications prescribed to persons with sch... 17317446 - Are there any news about the antipsychotic medications in the elderly? 7411556 - Research opportunities for medical students: an approach to the physician-investigator ... 2923616 - Aversive conditioning of visual screening with aromatic ammonia for treating aggressive... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural Date: 2010-06-29 |
Journal Detail:
|
Title: The Annals of pharmacotherapy Volume: 44 ISSN: 1542-6270 ISO Abbreviation: Ann Pharmacother Publication Date: 2010 Jul-Aug |
Date Detail:
|
Created Date: 2010-07-01 Completed Date: 2010-10-08 Revised Date: 2011-11-10 |
Medline Journal Info:
|
Nlm Unique ID: 9203131 Medline TA: Ann Pharmacother Country: United States |
Other Details:
|
Languages: eng Pagination: 1171-80 Citation Subset: IM |
Affiliation:
|
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Age Factors Antipsychotic Agents / adverse effects, therapeutic use* Basal Ganglia Diseases / chemically induced*, drug therapy Child Child, Preschool Cholinergic Antagonists / therapeutic use* Dibenzothiazepines / adverse effects, therapeutic use Drug Therapy, Combination Female Follow-Up Studies Humans Male Piperazines / adverse effects, therapeutic use Quinolones / adverse effects, therapeutic use Retrospective Studies Risperidone / adverse effects, therapeutic use |
| Grant Support | |
ID/Acronym/Agency:
|
K08 MH083888-02/MH/NIMH NIH HHS; K08 MH083888-04/MH/NIMH NIH HHS; UL1RR029879/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents; 0/Cholinergic Antagonists; 0/Dibenzothiazepines; 0/Piperazines; 0/Quinolones; 0/quetiapine; 106266-06-2/Risperidone; 129722-12-9/aripiprazole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Management of hypertension in renal transplant patients: a comprehensive review of nonpharmacologic ...
Next Document: A review of oral antiretroviral therapy for the treatment of chronic hepatitis B.